| Date |
Event |
Presentation |
Speakers |
|
April 6, 2013
|
AACR Annual Meetings
|
Expanding the Druggable Genome Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN
|
Domagoj Vucic
|
|
|
|
Mitotic Checkpoints Driving Cancer Therapeutic Strategies Chairperson: Peter K. Jackson, Genentech, Inc., South San Francisco, CA
|
Peter K Jackson
|
|
January 12, 2011
|
Antibodies for the 21st Century
|
Endogenous Anti-IFNa Autoantibodies in Patients with Systemic Lupus Erythematosus are Associated with Decreased IFN-Pathway and Disease Activity
|
Alyssa Morimoto
|
|
May 17, 2010
|
Phage and Yeast Display of Antibodies and Proteins
|
Chairperson’s Opening Remarks
|
Sachdev Sidhu
|
|
October 6, 2009
|
Phage Display to Develop Therapeutic Antibodies
|
Synthetic PDZ Domains for Functional Genomics
|
Sachdev Sidhu
|
|
|
|
Antibody Fragments and Scaffolds
|
Sachdev Sidhu
|
|
December 7, 2008
|
Antibody Engineering
|
Highly Functional Minimalist Antibodies
|
Sachdev Sidhu
|
|
April 30, 2008
|
Assessment of Immunogenicity in Clinical Trials
|
Case Study –Risk-based Immunogenicity
|
Valerie Quarmby
|
|
April 28, 2008
|
Clinical Development of Therapeutic Antibodies
|
The Development of Antiangiogenics in Lung Cancer
|
Jane Huang
|
|
April 27, 2008
|
Phage Display of Antibodies and Peptides
|
Chairperson’s Remarks
|
Dev Sidhu
|
|
|
|
Synthetic Antibodies
|
Germaine Fuh
|
|
April 27, 2008
|
Phage Display of Antibodies and Peptides
|
Synthetic Antibodies
|
Germaine Fuh
|
|
November 12, 2007
|
Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14)
|
Analysis of Protein Glycosylation (10:45-13:25)
|
An Song
|
|
|
|
Analysis of Protein Glycosylation:Anticipating Effects of Glycosylation on Effector Functions (10:45-11:15)
|
An Song
|
|
|
|
Causes and Assessment of Product and Process-Related Impurities (13:25-18:30)
|
Fred Jacobson
|
|
|
|
Causes and Assessment of Product and Process-Related Impurities:Protein Aggregation and Bioprocessing (13:30-14:00)
|
Fred Jacobson
|
|
|
|
Early Formulation Development (08:15-09:15)
|
Jim Andya
|
|
|
|
Early Formulation Development: Early Development Screening of Monoclonal Antibody Formulations (08:15-08:45)
|
Jim Andya
|
|
|
|
Process and Analytical Related Issues (15:30-17:00)
|
Ron Taticek
|
|
|
|
Process and Analytical Related Issues: Quality by Design in the Development of Post-Approval Changes for Cell Culture Processes (15:30-16:00)
|
Ron Taticek
|
|
November 7, 2007
|
Antibodies Europe: Engineering the Next Generation of Antibodies Nov (07-08)
|
Engineering Therapeutics (10:00-11:30)
|
Robert Kelley
|
|
|
|
Engineering Therapeutics: Fc Engineering of Therapeutic Antibodies (10:00-10:30)
|
Robert Kelley
|
|
November 7, 2007
|
Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13)
|
Session 7: Anti-Cancer/Tumors Drug Discovery & Development and Current Status of the Innovative Therapeutics (Part II) (09:00-12:00)
|
Mark S. Dennis
|
|
|
|
Session 7: Tumor Targeting with an AB.Fab (09:00-09:20)
|
Mark S. Dennis
|
How We Rank